- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07654296
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery
Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters. This prospective open-label interventional single-center study will compare 30-day postoperative patient reported outcomes and pain medication use between a pre-implementation cohort of patients managed with standard-of-care multimodal analgesia after ureteroscopy with a post-implementation cohort of patient with this regimen and addition of suzetrigine. The primary outcome will be opioid usage after discharge with standard of care multimodal analgesia (historical control) vs opioid usage after discharge with suzetrigine included with the standard of care
multimodal analgesia regimen (intervention). Secondary outcomes will include unplanned care encounters within 30 days (Emergency Room, unplanned clinic visits) and surveyed patient reported outcomes measured on a post-operative survey including PROMIS (Patient-Reported Outcomes Measurement Information System) questions as well as an end of study administration of WISQOL (The Wisconsin Stone Quality of Life Questionnaire). The study will be conducted within a single academic institution including the primary hospital (Brigham and Women's Hospital) and satellite sites (Brigham and Women's Faulkner Hospital).
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Daniel A Wollin, MD, MS
- Telefonszám: 617 732 6354
- E-mail: dwollin@mgb.org
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Christopher Magnani, MD, MS, MPhil
- E-mail: CMAGNANI@BWH.HARVARD.EDU
Tanulmányi helyek
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Toborzás
- Brigham and Women's Hospital
-
Kapcsolatba lépni:
- Daniel A Wollin, MD, MS
- Telefonszám: 617 732 6354
- E-mail: dwollin@mgb.org
-
Boston, Massachusetts, Egyesült Államok, 02130
- Toborzás
- Brigham and Women's Faulkner Hospital
-
Kapcsolatba lépni:
- Daniel A Wollin, MD, MS
- Telefonszám: 617 732 6354
- E-mail: dwollin@mgb.org
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham & Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).
- Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)
Exclusion Criteria:
- Regular opioid use prior to surgery or significant substance abuse concerns.
- Inability of patient to provide their own consent (i.e. lack capacity).
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: multimodal analgesia pathway (standard, no suzetrigine)
multimodal analgesia pathway without suzetrigine |
multimodal analgesia regimen |
|
Kísérleti: suzetrigine with multimodal analgesia pathway
addition of suzetrigine to multimodal analgesia pathway |
suzetrigine with multimodal analgesia regimen |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Post-discharge opioid consumption (MME)
Időkeret: 1-2 weeks
|
assessed at post-operative visit |
1-2 weeks
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Post-discharge opioid consumption (MME)
Időkeret: 30 days
|
assessed at 30 days after surgery |
30 days
|
|
Rate of unplanned care encounters
Időkeret: 30 days
|
Emergency Room visits |
30 days
|
|
patient reported outcomes: pain score
Időkeret: 2 weeks
|
measured on a 0 to 10 analog scale on post-operative survey |
2 weeks
|
|
patient reported outcomes: pain score
Időkeret: 30 days
|
measured on a 0 to 10 analog scale on post-operative survey |
30 days
|
|
patient reported outcomes: PROMIS composite score
Időkeret: 2 weeks
|
total score where each of the following is rated from 0 to 4 then aggregated into a total value:
|
2 weeks
|
|
patient reported outcomes: PROMIS composite score
Időkeret: 30 days
|
total score where each of the following is rated from 0 to 4 then aggregated into a total value:
|
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your day-to-day activities
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your day-to-day activities
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with work around the home
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with work around the home
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your ability to participate in social activities
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your ability to participate in social activities
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your household chores
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your household chores
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with things you usually do for fun
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with things you usually do for fun
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
|
patient reported outcomes (PROMIS) pain interfere with your enjoyment of social activities
Időkeret: 2 weeks
|
rated from 0 to 4 |
2 weeks
|
|
patient reported outcomes (PROMIS) pain interfere with your enjoyment of social activities
Időkeret: 30 days
|
rated from 0 to 4 |
30 days
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
Egyéb vizsgálati azonosító számok
- 2026P000126
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
This trial is being performed at within a single institution (Mass General Brigham) at two of it's constituent sites (BWH and BWFH), as part of IRB approval of the study decision was for privacy policy that only aggregated data would be intended to be shared outside the institutions system and any IPD would be solely stored on HIPAA compliant servers at the facility. De-identified or aggregated data would be permitted to be shared so long as subjects could not be identified.
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .